Almac Group Increase Early Phase "Hit to Lead" Chances With Pre-Clinical Screening Packages

October 10, 2012 -- Almac’s solid state services group have created a series of pre-clinical screening packages for clients to identify their candidate’s chances of success much quicker than using traditional mechanisms.

The package, a unique offering within solid state services companies, utilises a smart, fast and economical approach for lead identification. Designed to identify candidates with drug product like characteristics, it will also highlight the potential pitfalls associated with the molecules. Experimental efforts concentrate on establishing the physical/chemical, solubility, stability and polymorphic characteristics of each candidate. The information generated can then be used to make a rational decision for lead identification.

Commenting on the launch of this extended offering, Linda McCausland, Head of Physical Sciences, said:
“We are excited to be in a position to offer this package to our clients. Not only is it affordable, but its output will allow a rapid decision on whether to progress candidates further through early stage development. With speed to market being the most critical factor in sustainable drug development, utilising this service can make a real difference in investment and timelines.”

Established in 2008, Almac’s solid state services group are equipped with state of the art analytical research and development technologies and specialise in solid form characterisation, screening and selection and crystallisation process development.

For further information, Almac will be exhibiting at the forthcoming CPhI (Booth 10E41) and AAPS (Booth 3027) conferences.

The Almac Group provides a broad range of services from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRS® technology (IVRS/IWRS), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 3,300 individuals and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California.